OncLive TV

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Jeremy S. Abramson, MD, discusses the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma.

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

Maurie Markman, MD, discusses the need for comparative clinical trials with PARP inhibitors in ovarian cancer.

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

Katianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.